A devastating respiratory infection once thought to be primarily a childhood concern is making an alarming comeback among adults, catching the medical community and patients completely off guard.
ILiAD Biotechnologies says it hit a homer in a whooping cough vaccine challenge trial. The biotech linked its nasal vaccine to protection against colonization by the pathogen, causing the phase 2b ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results